Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Connect Biopharma Holdings Ltd
Cash & Cash Equivalents
Connect Biopharma Holdings Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
Cash & Cash Equivalents
¥78.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
¥15.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash & Cash Equivalents
¥17.3B
|
CAGR 3-Years
157%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Cash & Cash Equivalents
¥1.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash & Cash Equivalents
¥8.8B
|
CAGR 3-Years
62%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Cash & Cash Equivalents
¥1.5B
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Connect Biopharma Holdings Ltd
Glance View
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
See Also
What is Connect Biopharma Holdings Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
78.2m
CNY
Based on the financial report for Dec 31, 2025, Connect Biopharma Holdings Ltd's Cash & Cash Equivalents amounts to 78.2m CNY.
What is Connect Biopharma Holdings Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-40%
Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for Connect Biopharma Holdings Ltd have been -48% over the past three years , -40% over the past five years .
